一药治三病！辉瑞(PFE.US)&艾伯维(ABBV.US)小分子疗法获批上市

智通财经04-23

智通财经APP获悉，辉瑞(Pfizer/PFE.US)宣布，欧盟委员会(EC)批准其与艾伯维(AbbVie/ABBV.US)联合开发的Emblaveo(aztreonam-avibactam)上市，用于治疗成人复杂性腹腔内感染(cIAI)、医院获得性肺炎(HAP，包括呼吸机相关性肺炎[VAP])，以及复杂性尿路感染(cUTI，包括肾盂肾炎)。该药物还适用于治疗由需氧革兰氏阴性菌引起感染的成人患者，这些患者的治疗选择有限。

根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。

据悉，抗菌素耐药性(AMR)是指细菌、病毒、真菌和寄生虫发生变异，产生抵抗抗菌药物的现象，这被认为是全球健康的最大威胁之一。

安全性方面，Emblaveo耐受性良好，没有新的安全性发现，其安全性与aztreonam单独使用时相似。Emblaveo是aztreonam和avibactam这两种抗生素的组合。

Emblaveo由辉瑞与艾伯维联合开发。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2429139311?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-23 11:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2429139311","market":"hk","top_or_hot":-1,"title":"一药治三病！辉瑞(PFE.US)&艾伯维(ABBV.US)小分子疗法获批上市","media":"智通财经","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(Pfizer/PFE.US)宣布，欧盟委员会(EC)批准其与艾伯维(AbbVie/ABBV.US)联合开发的Emblaveo(aztreonam-avibactam)上市，用于治疗<strong>成人复杂性腹腔内感染</strong>(cIAI)、<strong>医院获得性肺炎</strong>(HAP，包括<strong>呼吸机相关性肺炎[VAP])，以及复杂性尿路感染</strong>(cUTI，包括肾盂肾炎)。该药物还适用于治疗由需氧革兰氏阴性菌引起感染的成人患者，这些患者的治疗选择有限。</p><p>根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。</p><p>据悉，抗菌素耐药性(AMR)是指细菌、病毒、真菌和寄生虫发生变异，产生抵抗抗菌药物的现象，这被认为是全球健康的最大威胁之一。</p><p>安全性方面，Emblaveo耐受性良好，没有新的安全性发现，其安全性与aztreonam单独使用时相似。Emblaveo是aztreonam和avibactam这两种抗生素的组合。</p><p>Emblaveo由辉瑞与艾伯维联合开发。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>一药治三病！辉瑞(PFE.US)&艾伯维(ABBV.US)小分子疗法获批上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n一药治三病！辉瑞(PFE.US)&艾伯维(ABBV.US)小分子疗法获批上市\n</h2>\n\n<h4 class=\"meta\">\n\n<p class=\"head\">\n<strong class=\"h-name small\">智通财经</strong><span class=\"h-time small\">2024-04-23 11:25</span>\n</p>\n\n</h4>\n\n</header>\n<article>\n<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(Pfizer/PFE.US)宣布，欧盟委员会(EC)批准其与艾伯维(AbbVie/ABBV.US)联合开发的Emblaveo(aztreonam-avibactam)上市，用于治疗<strong>成人复杂性腹腔内感染</strong>(cIAI)、<strong>医院获得性肺炎</strong>(HAP，包括<strong>呼吸机相关性肺炎[VAP])，以及复杂性尿路感染</strong>(cUTI，包括肾盂肾炎)。该药物还适用于治疗由需氧革兰氏阴性菌引起感染的成人患者，这些患者的治疗选择有限。</p><p>根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。</p><p>据悉，抗菌素耐药性(AMR)是指细菌、病毒、真菌和寄生虫发生变异，产生抵抗抗菌药物的现象，这被认为是全球健康的最大威胁之一。</p><p>安全性方面，Emblaveo耐受性良好，没有新的安全性发现，其安全性与aztreonam单独使用时相似。Emblaveo是aztreonam和avibactam这两种抗生素的组合。</p><p>Emblaveo由辉瑞与艾伯维联合开发。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。</p></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"http://www.zhitongcaijing.com/content/detail/1107359.html\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999003800.SGD","symbol_name":"Nikko AM Global Dividend Equity Acc SGD-H","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1107359.html","article_id":"2429139311","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2429139311","pubTimestamp":1713842723,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，辉瑞宣布，欧盟委员会批准其与艾伯维联合开发的Emblaveo上市，用于治疗成人复杂性腹腔内感染、医院获得性肺炎，以及复杂性尿路感染。根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。Emblaveo是aztreonam和avibactam这两种抗生素的组合。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4550":"红杉资本持仓","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","BK4568":"美国抗疫概念","IE0004445239.USD":"JANUS HENDERSON US FORTY \"A2\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","ABBV":"艾伯维公司","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","PFE":"辉瑞","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4534":"瑞士信贷持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","BK4566":"资本集团","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU1496350171.SGD":"FRANKLIN DIVERSIFIED BALANCED \"A\" (SGDHDG) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","BK4559":"巴菲特持仓"},"translate_title":"One medicine cures three diseases! Pfizer (PFE.US) & AbbVie (ABBV.US) Small Molecule Therapy Approved for Marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"PFE":1},"content_text":"智通财经APP获悉，辉瑞(Pfizer/PFE.US)宣布，欧盟委员会(EC)批准其与艾伯维(AbbVie/ABBV.US)联合开发的Emblaveo(aztreonam-avibactam)上市，用于治疗成人复杂性腹腔内感染(cIAI)、医院获得性肺炎(HAP，包括呼吸机相关性肺炎[VAP])，以及复杂性尿路感染(cUTI，包括肾盂肾炎)。该药物还适用于治疗由需氧革兰氏阴性菌引起感染的成人患者，这些患者的治疗选择有限。根据新闻稿，Emblaveo是首个在欧盟获批使用的β-内酰胺/β-内酰胺酶抑制剂组合，用于治疗由多重耐药革兰氏阴性菌引起的严重细菌感染成人患者。据悉，抗菌素耐药性(AMR)是指细菌、病毒、真菌和寄生虫发生变异，产生抵抗抗菌药物的现象，这被认为是全球健康的最大威胁之一。安全性方面，Emblaveo耐受性良好，没有新的安全性发现，其安全性与aztreonam单独使用时相似。Emblaveo是aztreonam和avibactam这两种抗生素的组合。Emblaveo由辉瑞与艾伯维联合开发。辉瑞拥有在美国和加拿大以外地区商业化该疗法的全球权利，而艾伯维则拥有Emblaveo在美国和加拿大的权利。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2429139311"}